1. Pink Sheet
  2. >>Market Access

Gottlieb Floats New Antibiotic Payment Model In LPAD Announcement

 
• By Derrick Gingery

US FDA Commissioner outlines licensing fee reimbursement arrangement intended to provide better financial incentives for development.

antibiotics, pills and injection

US FDA Commissioner Scott Gottlieb chose to focus on antimicrobial reimbursement ideas rather than development policy in his announcement of new draft guidance on the Limited Population Antibacterial Drug (LPAD) pathway that was issued June 12.

LPAD is designed to speed approvals of novel antibiotics for small populations with serious or

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

Trump Administration Push For Dismissal, Transfer Of Mifepristone Case Leaves Overhang For Pharma

 
• By Sarah Karlin-Smith

The Trump Administration requested a dismissal or transfer of a lawsuit seeking to tighten the safety requirements for the abortion pill mifepristone on procedural grounds, which still leaves the administration's position on the case's merits unclear.

Opioid Safety: US FDA Hears Mixed Messages On Adding Posmarketing Studies To Labeling

 
• By Sue Sutter

Some advisory committee members said adding quantitative data on misuse, abuse, opioid use disorder and overdose to labeling would be helpful, but others worried the two epidemiological studies were not sufficiently generalizable to a broader population.

Viatris Agrees To $335m Opioid Settlement Ending US State, Local Government Cases

 
• By Dean Rudge

Viatris joined Hikma and Amneal, in signing agreements for cash settlements that resolve allegations its practices fueled the US’ deadly opioid epidemic.